VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 5189 participants.

Also called NCT01130246

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 5,189 participants (enrolled count) (from the registry)
Sponsor
Anthera Pharmaceuticals (from the registry)
Registry
  • NCT NCT01130246
Other papers using this trial's data
  • Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial JAMA, 2014-01-15 DOI, PubMed 24247616

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Australia, Canada, Czechia, Georgia, Germany, Hungary, India, Italy, Lebanon, Netherlands, New Zealand, Poland, Russia, South Korea, Spain, Ukraine (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01130246. Randomized; double masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2012-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome
Acronym
VISTA-16
Condition
Acute Coronary Syndrome
Intervention (Drug)
A-002, varespladib methyl
Intervention (Drug)
Placebo
Lead sponsor
Anthera Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01130246
Content hash
09b2102c413150fac32c0acd259f50c10e16dcd9965dddeba09b8aceb25312ff